RxSight, Inc. Announces Pricing of Initial Public Offering_老虎社区_美港股上老虎

RxSight, Inc. Announces Pricing of Initial Public Offering

StreetInsider2021-07-30

ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Ong86
·2021-07-30
Wow
回复
点赞
举报
Yujing
·2021-07-30
comment
回复
1
举报
收起
- BBKK:
  Comment
  2021-07-30
  回复
  举报
- Yujing:
  Comment
  2021-08-04
  回复
  举报
- Yujing:
  Comment
  2021-08-05
  回复
  举报
查看更多 2 条评论
4a650fb1
·2021-07-30
Like please
回复
2
举报
收起
- Sfun:
  ok
  2021-07-30
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2155138280?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-30 10:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2155138280","market":"us","top_or_hot":-1,"title":"RxSight, Inc. Announces Pricing of Initial Public Offering","media":"StreetInsider","content":"<div>\n<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744480\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight, Inc. Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight, Inc. Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744480><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744480\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=18744480","article_id":"2155138280","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2155138280","pubTimestamp":1627612800,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device c","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc."},"translate_title":"RxSight,Inc.宣布首次公开发行定价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRCT":0.9,"TERN":0.9},"content_text":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.\nJ.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.\nA registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:\n\nJ.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;\nBofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or\nSVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":806931319,"gmtCreate":1627622915231,"gmtModify":1633757662153,"author":{"id":"3555051353508945","authorId":"3555051353508945","authorIdStr":"3555051353508945","name":"Ong86","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3555051353508945"},"htmlText":"Wow&nbsp;","listText":"Wow&nbsp;","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806931319","repostId":2155138280,"repostType":4,"repost":{"id":"2155138280","pubTimestamp":1627612800,"share":"https://www.laohu8.com/m/news/2155138280?lang=&edition=full","pubTime":"2021-07-30 10:40","market":"us","language":"en","title":"RxSight, Inc. Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2155138280","media":"StreetInsider","summary":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device c","content":"<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.</p>\n<p>J.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.</p>\n<p>A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:</p>\n<ul>\n <li>J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;</li>\n <li>BofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or</li>\n <li>SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.</li>\n <li></li>\n</ul>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight, Inc. Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight, Inc. Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744480><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744480\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744480","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155138280","content_text":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.\nJ.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.\nA registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:\n\nJ.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;\nBofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or\nSVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806005280,"gmtCreate":1627614414840,"gmtModify":1633757747425,"author":{"id":"4090414284911250","authorId":"4090414284911250","authorIdStr":"4090414284911250","name":"Yujing","avatar":"https://static.tigerbbs.com/02fbe7d7a63f23b48d28c901537868da","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090414284911250"},"htmlText":"comment","listText":"comment","text":"comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/806005280","repostId":2155138280,"repostType":4,"repost":{"id":"2155138280","pubTimestamp":1627612800,"share":"https://www.laohu8.com/m/news/2155138280?lang=&edition=full","pubTime":"2021-07-30 10:40","market":"us","language":"en","title":"RxSight, Inc. Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2155138280","media":"StreetInsider","summary":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device c","content":"<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.</p>\n<p>J.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.</p>\n<p>A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:</p>\n<ul>\n <li>J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;</li>\n <li>BofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or</li>\n <li>SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.</li>\n <li></li>\n</ul>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight, Inc. Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight, Inc. Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744480><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744480\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744480","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155138280","content_text":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.\nJ.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.\nA registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:\n\nJ.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;\nBofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or\nSVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375945,"gmtCreate":1627616095191,"gmtModify":1635164380987,"authorId":4089409912576010,"author":{"id":4089409912576010,"authorId":4089409912576010,"name":"BBKK","avatar":"https://static.tigerbbs.com/50e16ff101160c30777ec2fc744874fc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806005280,"type":1,"supId":0,"prevId":0,"content":"Comment ","text":"Comment ","html":"Comment "},{"id":5419514,"gmtCreate":1628038441650,"gmtModify":1635160689047,"authorId":4090414284911250,"author":{"id":4090414284911250,"authorId":4090414284911250,"name":"Yujing","avatar":"https://static.tigerbbs.com/02fbe7d7a63f23b48d28c901537868da","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806005280,"type":1,"supId":5375945,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"},{"id":5430531,"gmtCreate":1628124086301,"gmtModify":1635159819039,"authorId":4090414284911250,"author":{"id":4090414284911250,"authorId":4090414284911250,"name":"Yujing","avatar":"https://static.tigerbbs.com/02fbe7d7a63f23b48d28c901537868da","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806005280,"type":1,"supId":5375945,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"},{"id":5446267,"gmtCreate":1628247307212,"gmtModify":1635158517057,"authorId":4090414284911250,"author":{"id":4090414284911250,"authorId":4090414284911250,"name":"Yujing","avatar":"https://static.tigerbbs.com/02fbe7d7a63f23b48d28c901537868da","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806005280,"type":1,"supId":5375945,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"},{"id":5456709,"gmtCreate":1628344665697,"gmtModify":1635157616260,"authorId":4090414284911250,"author":{"id":4090414284911250,"authorId":4090414284911250,"name":"Yujing","avatar":"https://static.tigerbbs.com/02fbe7d7a63f23b48d28c901537868da","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806005280,"type":1,"supId":5375945,"prevId":0,"content":"Comment","text":"Comment","html":"Comment"}],"langContent":"EN"},{"id":806009774,"gmtCreate":1627613962498,"gmtModify":1631893677637,"author":{"id":"4087797722131370","authorId":"4087797722131370","authorIdStr":"4087797722131370","name":"4a650fb1","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087797722131370"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806009774","repostId":2155138280,"repostType":4,"repost":{"id":"2155138280","pubTimestamp":1627612800,"share":"https://www.laohu8.com/m/news/2155138280?lang=&edition=full","pubTime":"2021-07-30 10:40","market":"us","language":"en","title":"RxSight, Inc. Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2155138280","media":"StreetInsider","summary":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device c","content":"<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.</p>\n<p>J.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.</p>\n<p>A registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:</p>\n<ul>\n <li>J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;</li>\n <li>BofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or</li>\n <li>SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.</li>\n <li></li>\n</ul>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RxSight, Inc. Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRxSight, Inc. Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 10:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18744480><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18744480\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","CRCT":"Cricut, Inc."},"source_url":"https://www.streetinsider.com/dr/news.php?id=18744480","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155138280","content_text":"ALISO VIEJO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds to RxSight® from the offering are expected to be $117.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, RxSight has granted the underwriters a 30-day option to purchase up to an additional 1,102,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. RxSight’s common stock is expected to begin trading on the Nasdaq Global Market on July 30, 2021, under the ticker symbol “RXST.” The offering is expected to close on August 3, 2021, subject to the satisfaction of customary closing conditions.\nJ.P. Morgan Securities LLC and BofA Securities, Inc. are acting as joint book-running managers of the offering and as representatives of the underwriters. SVB Leerink LLC is also acting as a book-running manager of the offering. Wells Fargo Securities, LLC is acting as lead manager for the offering. BTIG, LLC is acting as co-manager for the offering.\nA registration statement relating to the shares being sold in this offering has been filed with the Securities and Exchange Commission and was declared effective on July 29, 2021. The offering is being made only by means of a prospectus. When available, a copy of the final prospectus may be obtained by contacting:\n\nJ.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com;\nBofA Securities, Inc. Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, by telephone at +1 (800) 294-1322 or by email at dg.prospectus_requests@bofa.com; or\nSVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: +1 (800) 808-7525, ext. 6105 or by email at syndicate@svbleerink.com.\n\n\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5375677,"gmtCreate":1627614068592,"gmtModify":1631893677639,"authorId":3579425512905776,"author":{"id":3579425512905776,"authorId":3579425512905776,"name":"Sfun","avatar":"https://static.tigerbbs.com/677878018d08b9f3288b2153431bff4a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806009774,"type":1,"supId":0,"prevId":0,"content":"o<u><u>k</u></u>","text":"o<u><u>k</u></u>","html":"o<u><u>k</u></u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":55,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}